Breaking News

AbbVie, Argenx In Immuno-oncology Collaboration

Argenx will receive an upfront payment of $40 million to license ARGX-115

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AbbVie has formed a collaboration with Argenx, a clinical-stage biopharmaceutical company, to develop and commercialize ARGX-115, Argenx’ preclinical-stage human antibody program targeting the novel immuno-oncology target GARP, a protein believed to contribute to immuno-suppressive effects of T-cells. “ARGX-115 has been developed in collaboration with an outstanding team of academics at the de Duve Institute/Université Catholique de Louvain through our Innovative Access Program, w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters